Ryker Hacking, Utah State University
During the summer of 2017, we successfully created the first synthesis of a recently-discovered natural molecule that has moderate ability to inhibit an enzyme called aldose reductase (AR), which contributes to various diabetic complications, including “cataracts, retinopathy, neuropathy, and nephropathy.” Given AR’s natural contribution to these diabetes-related retinal complications, it follows that such an inhibitor could be therapeutically useful in their prevention. In our presentation, we will share the results of our full synthesis, along with preliminary data of our natural molecule’s physiological properties.